Ambrilia Biopharma Inc.
TSX : AMB

Ambrilia Biopharma Inc.

June 07, 2007 09:30 ET

Annual General and Special Meeting of Shareholders of Ambrilia and Webcast

ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS

MONTREAL, QUEBEC--(Marketwire - June 7, 2007) - Ambrilia Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, announced today that it will hold its Annual General and Special Meeting of Shareholders on Thursday, June 14, 2007 at 10:30 a.m. ET at The Montreal Museum of Fine Arts, Auditorium Maxwell-Cummings, 1379 Sherbrooke Street West, Montreal, Quebec.

Mr. Stephen G. Sudovar, Executive Chairman of the Board and interim CEO, will chair the meeting which will be followed by a review of Ambrilia's R&D projects and recent developments, and future outlook. Mr. Sudovar will be joined by the Company's executive committee.

Ambrilia will host a live webcast with slides of the event. Interested parties may access the webcast and presentation at www.ambrilia.com, Investors section, Conference calls and webcasts.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer. Ambrilia's product portfolio includes promising anti-HIV treatments (PPL-100 and an HIV Integrase Inhibitor Program), two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145), a tumor and tumor-vasculature targeting (TVT) technology platform, as well as other anti-virals and immunomodulators. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for a $US17 million upfront payment, potential milestones that could reach $US212 million, and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site: www.ambrilia.com

Contact Information